window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : May 20, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Therapeutic Areas

  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    NICE expands Lokelma access for hyperkalaemia after draft recommendation

    The National Institute for Health and Care Excellence (NICE) has [...]

    May 5, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Manufacturing & Supply Chain,Therapeutic Areas

    Oncodesign expands ARRONAX deal to secure astatine-211 supply for radiotherapy research

    Oncodesign Services has expanded its collaboration with French research institute [...]

    May 5, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Regeneron enters radiopharmaceuticals through multi-programme collaboration with Telix in oncology expansion

    Regeneron Pharmaceuticals has entered the radiopharmaceuticals field through a multi-programme [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Emalex wins US patent for ecopipam ODT as Tourette access program grows

    Emalex has secured a US patent for an orally disintegrating [...]

    May 5, 2026
  • Drug Discovery & Development,Therapeutic Areas

    Kinesin-2 motor variants shown to control cargo transport in neurons

    Researchers in Japan have identified distinct kinesin-2 motor protein assemblies [...]

    May 5, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Delivery & Formulation,Drug Discovery & Development,Opinion & Events,Therapeutic Areas

    Emalex secures US patent for ecopipam orally disintegrating tablet in Tourette syndrome

    Emalex Biosciences has secured a US patent for an orally [...]

    May 5, 2026
  • Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Currax highlights peer-reviewed review supporting combination approaches in obesity treatment

    Currax Pharmaceuticals is highlighting a peer-reviewed publication supporting the use [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    MaaT Pharma publishes real-world CHRONOS data in third-line acute GvHD

    MaaT Pharma has published retrospective real-world data from its CHRONOS [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Kainova expands Phase 1/2 trial of DT-7012 with first European patient dosed

    Kainova Therapeutics has dosed the first European patient in its [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Therapeutic Areas

    European liver experts highlight rising MASLD burden at EASL symposium in Budapest

    European liver disease specialists have highlighted the growing burden of [...]

    May 5, 2026
Previous123Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • NETRIS Pharma Nature publishes pancreatic cancer Phase 1b data showing NP137 survival and surgery gains
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Drug Discovery & Development, Therapeutic Areas
  • Myomaker Bio launches lab-grown human muscle platform for preclinical drug testing
    Categories: Advanced Therapies, Biotech & Pharma Business, Clinical & Regulatory, Drug Discovery & Development
  • Abivax to present nine obefazimod studies at DDW as Phase 3 ulcerative colitis data build
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Opinion & Events, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top